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Occurrence of a multidrug-resistant phenotype in human lung xenografts
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Summary The intrinsic sensitivity of a panel of 8 human epidermoid lung cancer xenografts to vincristine
and actinomycin D has been examined and the cross-resistance patterns of the most vincristine-resistant and
vincristine-sensitive tumour line were tested to a variety of other drugs, including radiation. The results
demonstrate that xenograft lines derived from human lung tumours not previously treated with chemotherapy
exhibit a similar general pattern of cross-resistance to the drugs vincristine, actinomycin D and adriamycin as
is observed in human cell lines and in animal models selected for resistance to these drugs. It is also shown
that intrinsic resistance to vincristine can be partially overcome by verapamil. This may indicate a potential
role of this substance in circumventing clinically observed drug resistance.
The current treatment results of epidermoid lung cancer with
cytotoxic agents are disappointing. Objectively proven
tumour response can be achieved only in a small number of
patients and this response is generally short-lived with little
or no improvement in survival time. Neither the nature of
the intrinsic resistance of tumours which do not respond to
treatment nor the acquired resistance that can develop
following an initial response to chemotherapy has been well
characterized. Studies performed with cultured tumour cell
lines and transplantable tumours selected for resistance to a
single drug have shown that cross-resistance between antra-
cyclines, actinomycins and vinca alkaloids is a common
phenomenon. This phenomenon, known as multidrug resis-
tance or pleiotropic resistance, describes the simultaneous
expression of cellular resistance to a wide range of struc-
turally unrelated drugs (Biedler & Riehm, 1970; Dano, 1972;
Johnson et al., 1978; Kaye & Bowden, 1980). Reduced
cellular accumulation of the drugs as a consequence of
reduced drug influx or increased drug efflux appears to
account for this resistance (Beck, 1984; Riordan & Ling,
1985). Also an increased expression of a high molecular
weight, plasma membrane glycoprotein which correlates with
the degree of drug resistance, could be identified in
multidrug resistant cell lines (for survey see Gerlach et al.,
1986). Recently, Bell et al. (1985a, b) detected elevated levels
of such membrane proteins in biopsy specimens from
patients undergoing therapy for ovarian cancer and
sarcomas. These findings suggest that multidrug resistant
tumour cells also occur in human malignancies.
The question arises from these and other studies whether
multi-drug resistance occurs only in tumours selected for
resistance to a single drug or whether this phenomenon can
be detected also in tumours not previously treated with
chemotherapy.
In the present study we examined the intrinsic sensitivity
to vincristine and actinomycin D of eight human tumour
xenografts derived from epidermoid carcinomas of the lung
and describe the cross-resistance patterns of a vincristine-
resistant and sensitive tumour line to a variety of commonly
used cytotoxic agents, including radiation.
Materials and methods
Nude mice
NMRI (nu/nu) (nude) female mice, 6-10 weeks old, were
purchased from the Breeding Center, Hannover, FRG. The
animals were maintained by conventional methods in
Makrolon cages at 25°C and 50% humidity. Autoclaved feed
and acidified water were provided ad libitum.
Tumours
Eight human epidermoid lung carcinomas established as
xenografts in nude mice were used. All tumour lines were
not previously treated with chemotherapy and were derived
from untreated patients. Their characteristics, including
histology and growth rates, are presented in Table I. At the
time of this study, the light microscopical histologic appear-
ance of the 8 tumour lines was epidermoid carcinoma of the
lung. Cytogenetic studies revealed a human karyotype. The
tumour lines have been maintained by serial s.c. trans-
plantation of minced tumours into the right subaxillary
region (0.1 ml/mouse) (Mattern et al., 1985).
Chemotherapy and evaluation oftherapeutic effect
After the tumours had reached a mean diameter of 8- 0 mm,
the tumour-bearing mice were randomized into groups of 5-
7 animals each, and treatment with the drugs (as single i.p.
dose) or irradiation was started. Each drug was given at the
maximum-tolerated dose to the mouse. Vincristine (VCR, Eli
Lilly GmbH, Bad Homburg): 2 mgkg-1; actinomycin D
(AD, MSD Sharp & Dohme, GmbH): 0.5mgkg-1; adria-
mycin (ADM, Farmitalia Carlo Erba GmbH, Freiburg):
10mgkg-1; 5-fluorouracil (5-FU, Hoffman-La Roche, AG,
Grenzach): 200mgkg-1; cis-platin (DDP, Bristol-Myers
GmbH, Neu-Isenburg): 10mgkg-1; cyclophosphamide
(CTX, Asta-Werke Degussa, Bielefeld): 240mgkg-1; mel-
phalan (L-PAM, Deutsche Wellcome GmbH, Burgwedel):
12mgkg-1; verapamil (VER, Stadapharm GmbH, Bad
Wibbel): 25 mgkg-1.
All agents were injected in a volume of 0.02mlg-1 body
wt. Photon irradiation was performed with Co60 gamma
rays (Siemens, Erlangen). Dose: 10Gy.
The tumour growth was followed by measuring two
diameters daily with calipers. The tumour weight was calcu-
lated for an ellipsoid by the formula V=(a2 x b)/2, where a
is the width and b is the length in mm. This can be
considered a valid estimation of weight in mg, assuming unit
density (Geran et al., 1972). The tumour sizes were standard-
ized in the different groups by obtaining relative tumour
weight (RW) calculated by the formula RW= Wx/Wo, where
Wx is the mean tumour weight at any time given and Wo is
the mean initial tumour weight at the start of treatment. The
effect of drugs was expressed as a T/C-ratio (mean tumour
size of the treated tumour/mean tumour size of control
group) x 100. The lowest value was expressed as an optimal
T/C (%) for each group.
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Statistical analysis
Wilcoxon rank sum test was used to compare control groups
versus treated groups.
Results
In order to establish human lung tumour lines with different
sensitivity to vincristine, samples of human epidermoid lung
carcinoma lines which have been established in nude mice
and stored in liquid nitrogen were thawed and reimplanted
into nude mice. Eight tumour lines grew again, the histo-
logical features of these lines are summarized in Table I. All
tumours had not received prior chemo- or radiotherapy in
the clinical stage or as xenografts in nude mice. Tumour
mass doubling times in nude mice ranged between 2.7 and
7.7 days. The therapeutic responses of these 8 human
epidermoid lung tumours to a single dose of vincristine and
actinomycin D were assessed by plotting changes in relative
tumour size versus time and is shown in Figure 1. As
expected, the tumour lines responded differently to
vincristine (left) and actinomycin D (right). Some tumour
lines responded very strongly, whereas others showed only
little effect. Moreover, the tumour lines which were less
responsive to vincristine were also less responsive to actino-
mycin D, and conversely, the tumour lines which proved to
be sensitive to vincristine were also sensitive to actinomycin
D. When the effects of vincristine (expressed as optimal T/C-
values) on the 8 tumour lines are correlated with the effects
Table I Characteristics of eight human epidermoid lung cancer
xenografts lines in nude mice ranked according to the sensitivity to
vincristine (VCR)
Tumour Optimal
Tumour doubling time TIC value
No. line Differentiation (days) (%)
1 HXL 54 well 6.0 87
2 HXL 208 poorly 2.7 72
3 HXL 204 poorly 7.7 71
4 HXL 163 moderately 5.3 60
5 HXL 3 moderately 5.0 58
6 HXL 266 poorly 2.5 42
7 HXL 182 moderately 7.0 37
8 HXL 55 poorly 3.5 4
of actinomycin D, a close relationship can be found
(r=0.96). Actinomycin D which is structurally dissimilar to
vinca alkaloids shows cross-resistance to vincristine,
although the tumour lines were not treated with any of these
substances before.
Cross-resistance patterns for the most vincristine-resistant
line (HXL 54) and for the most vincristine-sensitive line
(HXL 55) are shown in Figures 2 and 3. With the tumour
line HXL 54, cross-resistance between vincristine, actino-
mycin D and adriamycin is apparent whereas collateral
sensitivity to all the other agents tested including irradiation
is observed. The tumour line HXL 55 shows sensitivity to all
drugs tested as well as to irradiation.
To investigate whether the calcium channel blocker
verapamil could overcome intrinsic resistance to vincristine
or could improve existing sensitivity, experiments were
carried out with the resistant tumour line HXL 54 and the
sensitive line HXL 55. Both tumour lines were treated
simultaneously with 25mgkg-1 verapamil and l mgkg- 1
vincristine. The results are shown in Table II. The dose of
25mgkg-' verapamil alone causes no inhibition of tumour
growth in both tumour lines. Whereas the resistance to
vincristine in the tumour line HXL 54 can partially be
overcome by the addition of verapamil (P 0.05), the sensi-
tivity of HXL 55 to vincristine cannot be substantially
influenced.
Discussion
The presence of drug-resistance in tumours is an important
clinical problem which is still far from being fully
understood. In the present study, we have investigated the
intrinsic resistance of a panel of 8 human epidermoid lung
cancer xenografts to vincristine and actinomycin D and
have tested the cross resistance patterns of a vincristine-
resistant and a vincristine-sensitive line to a variety of other
agents, including radiation.
From the results in Figure I it is apparent that xenografts
lines derived from human tumours not previously treated
with chemotherapy have different but parallel degrees of
inherent resistance to vincristine and actinomycin D. This is
not surprising considering the variable clinical response of
patients to chemotherapeutic agents, including vincristine
which has a response rate for lung carcinomas of about 10%
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Figure 1 Effect of a single dose of 2mgkg-1 vincristine (left) and 0.5mgkg-1 actinomycin D on the tumour size of 8 different
epidermoid lung cancer xenograft lines in nude mice.
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Figure 2 Cross-resistance patterns of the vincristine-resistant tumour line HXL 54. The points and the bars represent mean
values +s.d. P values as evaluated by the Wilcoxon rank sum test on day 10 between treated and control groups: VCR: 0.13; AD:
0.53; ADM: 0.24; 5-FU: 0.03; CTX: 0.0003; DDP: 0.0006 (day 9); L-PAM: 0.0012; Co60: 0.01.
Table II Effect of 25mgkg 1 verapamil and 1 mgkg - vincristine on the tumour size of the vincristine-
resistant tumour line HXL 54 (left) and the vincristine-sensitive line HXL 55 (right)
HXL 54 HXL 55
TIC (%) Mean RW' P value TIC (%) Mean RW P value
Control 2.31 +O0.54b Control 2.67+0.66
VER 95 2.19+0.46 VER 102 2.74+0.33
VCR 87 2.00+0.23 P< 05 VCR 45 0.85+0.26| NSC
VCR+VER 63 1.46+0.25 J VCR+VER 39 0.74+0.09 J
aRW=relative tumours weights on day 6 after treatment; beach results represents mean+s.d.; CNS=not
significant.
as a single agent in untreated patients (Bakowski & Crouch,
1983).
However, the question whether cells with a multidrug
resistant phenotype are also present in situ in human
tumours, is of clinical importance. There are only few
clinical data regarding the emergence of multidrug-resistance
and it is not clear whether cross-resistance between anti-
biotics, anthracyclines and vinca alkaloids is a common
finding. Attempts to demonstrate the presence of multidrug-
resistant cells in human tumours have involved in vitro
colony-forming assays in soft agar (Shoemaker et al., 1983)
or assays which measure the ability of tumour cells to
incorporate labelled precursors in the presence of cytotoxic
drugs (Bech-Hansen et al., 1977; Volm et al., 1979).
From our study, it is clear, under the experimental con-
ditions employed, that intrinsic resistance to vincristine is
correlated with resistance to actinomycin D. Although the
HXL 54 which is a well differentiated tumour with a
relatively slow growth rate was found to be more resistant to
all the agents tested including irradiation than, for instance,
HXL 55 which is poorly differentiated and faster growing,
the close relationship between the effects of vincristine and
actinomycin D for the eight tumour lines supports the
concept of cross-resistance between these two agents. The
collateral sensitivity to alkylating agents and to antimetabo-
lites which is often observed in a number of multidrug
resistant cell lines, is also found in the resistant tumour line
HXL 54 with CTX and DDP but is not so evident with 5-
VCR AD
10
5
1 0
4
01 i
E
+_1
a, 5-
10
CTX DDP
0.1
0 2 4 6 8
T |-
1410 J. MATTERN et al.
10 VCR AD j ADM 5-FU
5
0.1 t T 7 1 T I l 7------- T S T
o
E 10
1 T_
0. t 1 F T F I- F ;F r F - - TF FX F
0 2 4 6 8 10 0 2 4 6 8 10 0 2 4 6 8 10 0 2 4 6 8 10
Days after treatment
Figure 3 Cross-resistance patterns of the vincristine-sensitive tumour line HXL 55. The points and the bars represent mean
values+s.d. P values: VCR: 0.001; AD: 0.004 (day 7); ADM: 0.004; 5-FU: 0.01; CTX: 0.001; DDP: 0.002; L-PAM: 0.02; Co60:
0.02.
FU and L-PAM. Conter and Beck (1984) have shown that
the cross-resistance pattern of a VCR-resistant cell line to
other agents was dependent on the degree of VCR resistance
and that the degree of cross-resistance can vary considerably
among the different cell lines, regardless of the selection
agent or the extent of primary resistance. Furthermore,
comparable degrees of resistance to one drug do not
necessarily predict comparable degrees of cross-resistance to
other drugs. The tumour line HXL 208 which is also
relatively resistant to VCR and AD and reveals a similar
growth rate as HXL 55, shows also a collateral sensitivity to
CTX (optimal T/C value on day 10: 25%; P=0.003).
Previously, Merry et al. (1984) reported on the inherent
sensitivity of six cell lines established from human gliomas to
cytotoxic drugs and could demonstrate a similar pattern of
cross-resistance as found in multidrug-resistant cell lines.
These results led to the assumption that mechanisms
involved in inherent resistance are perhaps related to those
found in multidrug resistant cells.
A wide spectrum of drugs, including many that do not
possess antitumour activity, have been demonstrated to
potentiate the cytotoxic effects of some antineoplastic agents
(for survey see Kessel, 1986). Verapamil, a calcium
antagonist widely used in cardiological medicine, has been
shown to be a potent modifier of vincristine resistance. In
our studies, we found that verapamil (25mgkg-1) in vivo is
able to increase vincristine cytotoxicity of the resistant line
HXL 54, but not of the sensitive line HXL 55. These data
are consistant with results of other authors who demon-
strated that verapamil increased vincristine cytotoxicity in
drug resistant cells in vitro (Tsuruo et al., 1981, 1982). Thus,
verapamil is able to potentiate both inherent and induced
resistance and this indicates a potential role for verapamil in
circumventing clinically observed drug resistance.
In conclusion, our results demonstrate that xenograft lines
derived from human lung tumours not previously treated
with chemotherapy exhibit a similar general pattern of cross-
resistance to the drugs vincristine, adriamycin and actino-
mycin D as is observed in multidrug-resistant human cell
lines and in animal tumour models and that the intrinsic
resistance to vincristine can be partially overcome by
verapamil.
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